A preservative free generic alternative to DuoNeb® (Ipratropium Bromide Bar Coded; Available in the following package configurations per box. Mylan Specialty: DuoNeb is indicated for the treatment of bronchospasm associated with COPD in patients requiring more than one. Prescription Drug Information: Duoneb. Ritedose Pharmaceuticals DUONEB- ipratropium bromide and albuterol sulfate solution. Ritedose.
|Published (Last):||10 November 2009|
|PDF File Size:||19.97 Mb|
|ePub File Size:||7.78 Mb|
|Price:||Free* [*Free Regsitration Required]|
Send the page ” ” to a friend, relative, colleague or yourself. We do not record any personal information entered above.
Inhaled combination of a short-acting beta agonist SABAalbuterol, with a short-acting antimuscarinic agent, ipratropium Primarily used in the treatment duineb COPD in adults, also used off-label for the acute management of asthma in adult and pediatric patients Available as oral inhalation or nebulizer solution; combination therapy produces a greater effect than either drug alone.
Each actuation delivers mcg of albuterol equivalent to mcg of albuterol pacoage and 20 mcg of ipratropium bromide monohydrate.
Patients may take additional inhalations as required. The combination is indicated for COPD patients who are receiving a regular aerosol bronchodilator and who continue to have evidence of bronchospasm which requires a second bronchodilator.
Evidence does not support the djoneb of high doses of albuterol on an “as needed” basis in patients already treated with long-acting bronchodilators.
Albuterol; ipratropium may also be used for acute COPD exacerbations. One 3-mL vial inhaled via nebulizer 4 times per day. Each 3-mL vial contains 3 mg albuterol sulfate 2.
Up to 2 additional 3-mL doses may be allowed per day, if needed. Additional doses and increased frequency of administration beyond these guidelines have not been studied. The safety and efficacy of extra doses of albuterol or ipratropium in addition inert the doses of the combination product have not been studied.
For an acute asthma exacerbation, the NAEPP recommends 3 mL inhaled via a nebulizer every 20 minutes for 3 doses, then as needed. Ipratropium may provide packagd additive benefit to inhaled betaagonists when treating severe acute asthma exacerbations in the emergency department and, in some instances, during medical transport.
Safe and effective use of Combivent Respimat inhalation spray not established; one 3-mL vial per dose of nebulizer solution e. Safe and effective use of Combivent Respimat inhalation spray not established; 1. Specific guidelines for dosage adjustments in hepatic impairment are not available; it appears that no dosage adjustments are needed.
Specific guidelines for dosage inert in renal impairment are not available; it appears that no dosage adjustments are needed. Solution for nebulization Duoneb: No need for dilution prior to use. The choice of using a mouthpiece versus a face mask must be made based on the skills and understanding of each individual patient. Using the ‘blow by’ technique i. If the patient is using other nebulized medications, instruct them to use innsert ipratropium first and wait 10 minutes before using other nebulized medications as directed.
Inhalation spray Combivent Respimat: Ihsert patient on proper inhalation technique according to product directions. Prior to first use, insert the cartridge into the inhaler and prime the unit by actuating the inhaler toward the ground until an aerosol cloud is visible and then repeating the process three more times. The unit is then considered primed and ready for use.
If not used for more than 3 days, patients are to inset the inhaler once to prepare the inhaler for use. If not used for more than 21 days, patients are to pckage the inhaler until an aerosol cloud is visible and packkage repeat the process three more times to prepare the inhaler for use. To inhale a dose: Hold the inhaler upright with the orange cap closed, so as to not accidentally release a dose of medicine.
Turn the clear base in the direction of the white arrows on the label until it clicks half a turn. Then, flip the orange cap until it snaps fully open. Have patient breathe out slowly and fully, and then close their lips around the end of the mouthpiece without covering the air vents. Point the inhaler to the back of your throat. While the patient takes packaye a slow, deep breath through the mouth, press duonwb dose release button and continue to have the patient breathe in slowly for as long as the patient can.
The patient should hold the breath for 10 seconds or for as long as comfortable. Close the orange cap until it is time to use the inhaler again. The mouthpiece, including the metal part inside the mouthpiece, should be cleaned with a dhoneb cloth or tissue only, at least 1 time a week; any minor discoloration in the mouthpiece does not affect the inhaler.
Ipratropium Bromide mg and Albuterol Sulfate 3mg | Nephron Pharmaceuticals
If the outside of the inhaler gets dirty, wipe it with a damp cloth. The inhaler contains 60 puffs or puffs, equal to 60 doses or doses. The dose indicator shows approximately how much medicine is left. When the pointer enters the red area of the scale, there is enough medicine for 3 days 60 dose product or 7 days dose product ; once the dose indicator has reached the end of the scale, all 60 or puffs have been used and the inhaler locks automatically.
At this point, the base cannot be turned any further. The inhaler should be discarded 3 months after insertion of cartridge into inhaler, even if all the medicine has not been used, or when the inhaler is locked after 60 or puffswhichever comes first. To avoid the spread of infection, do not use the inhaler spray for more than one person. The Combivent albuterol; ipratropium aerosol contains flammable ingredients under pressure.
To avoid injury, the aerosol should be kept away from extreme heat or flames and the container should not be punctured. Do not exceed recommended dosages of beta-agonists; fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. The exact cause of death is unknown, but cardiac arrest after an unexpected development of a severe acute asthmatic crisis and subsequent hypoxia is suspected.
Albuterol; ipratropium aerosols can produce a paradoxical bronchospasm that can be life-threatening in some patients. If bronchospasm occurs, the albuterol; ipratropium inhalation should be discontinued immediately and appropriate treatment measures instituted. In rare cases severe allergic reactions, including urticaria, angioedema, oropharyngeal edema, respiratory difficulty, and anaphylaxis have occurred following the use of either albuterol or ipratropium. Albuterol; ipratropium combinations are contraindicated in patients with atropine hypersensitivity, albuterol hypersensitivity, or their respective derivatives e.
Use albuterol; ipratropium with caution in patients with cardiac disease or other conditions that may increase the risk of QT prolongation including cardiac arrhythmias, congenital long QT syndrome, heart failure, bradycardia, myocardial infarction, hypertension, coronary artery disease, hypomagnesemia, hypokalemia, hypocalcemia, or in patients receiving medications known to prolong the QT interval or cause electrolyte imbalances. Females, elderly patients, patients with diabetes, thyroid dysfunction, malnutrition, alcoholism, or hepatic dysfunction may also be at increased risk for QT prolongation.
At excessive use or dosages, beta-agonists may produce a transient hypokalemia, which might produce adverse effects in susceptible individuals with cardiac disease, particularly those patients on non-potassium sparing diuretics. Due to the anticholinergic effects of ipratropium, albuterol; ipratropium combinations should be used with caution in some patient populations. Ipratropium may precipitate urinary retention in patients with preexisting bladder obstruction of the bladder neck or prostatic hypertrophy.
Although inhaled ipratropium is only minimally absorbed into the systemic circulation, the effects of ipratropium may be additive to other anticholinergic medications. Clinical studies of albuterol; ipratropium inhalers and nebulizer solutions have included a fair percentage of older adults 65 years and over, and patients 75 years of age and older.
No overall differences in safety or effectiveness were observed, and other reported clinical experience has not identified differences in responses. Geater sensitivity of some older individuals cannot be ruled out. Geriatric patients may generally be more sensitive to the side effects of inhaled beta-agonist and anticholinergic therapies and be more likely to experience side effects such as dry mouth or constipation.
Albuterol may exacerbate conditions that are responsive to sympathomimetic stimulation, such as hyperthyroidism thyrotoxicosis, thyroid diseaseconvulsive disorders, diabetes mellitus, seizure disorder or seizures, or hypersensitivity to sympathomimetics pheochromocytoma. Caution should be used when albuterol; ipratropium is prescribed to these individuals.
Ipratropium may increase intraocular pressure and aqueous outflow resistance in patients with closed-angle glaucoma, particularly if the medication gets into the eyes. Temporary pain, mydriasis, cycloplegia, blurred vision, conjunctivitis, or visual impairment may result from inadvertent ophthalmic administration. Care should be taken not to spray albuterol; ipratropium in the eyes.
The anticholinergic effects of ipratropium may make the eyes dry and this can cause irritation or blurred vision for wearers of contact lenses. The use of lubricating drops may be necessary. Albuterol; ipratropium inhalation combinations are classified as FDA pregnancy risk category C. Albuterol inhalation is classified as a category C drug. In animals, a small increase in craniofacial defects has been seen with systemically administered albuterol. Most adverse effects observed in human pregnancy are a result of the cardiovascular and metabolic effects of albuterol.
Maternal and fetal tachycardia and maternal hypotension have occurred with systemic use of the beta-agonists. Due to the potential for interference with uterine contractility, use of albuterol; ipratropium during labor and obstetric delivery should be restricted to those patients in whom the benefits clearly outweigh the risks.
Several studies of inhaled beta-agonist use during pregnancy have not noted an increase in either congenital malformations or other adverse perinatal outcomes.
Ipratropium inhalation is classified as a pregnancy category B drug. Teratogenesis has not been reported in animals or humans with the use of ipratropium aerosols; but study in humans is limited. Albuterol; ipratropium aerosol combinations should be used during pregnancy only if the benefit to the mother outweighs the potential risks to the fetus. Caution should be exercised in lactating mothers who may require albuterol; ipratropium combinations. It is unknown if albuterol is excreted into human milk; however, the manufacturer recommends that due to the potential for tumorigenicity in animal studies, a decision should be made to discontinue nursing or to discontinue albuterol; ipratropium.
Other beta-agonist medications, like terbutaline, are excreted in breast milk in small amounts and are generally considered compatible with breast-feeding by the American Academy of Pediatrics. According to the recommendations of the National Asthma Education and Prevention Program for managing asthma during pregnancy, there is currently dupneb contraindication for use of short-acting inhaled beta-2 agonists during lactation.
Ipratropium, when administered by aerosol, is also excreted into breast-milk in minimal amounts. Atropine, a drug related to ipratropium, is usually considered compatible with breast-feeding by the American Academy of Pediatrics. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition.
If a breast-feeding infant experiences an adverse effect related to a maternally administered drug, healthcare providers are encouraged to report the adverse effect to the FDA.
The safety and effectiveness of albuterol; ipratropium fixed-dose combinations has not been established in infants and children. The use of albuterol; ipratropium has not been adequately studied in patients with renal impairment including renal failure, renal disease or hepatic disease.
Beta2-agonists should be administered with douneb caution to patients being treated with Duonebb therapy see Drug Interactions. Advise patients receiving albuterol; ipratropium to use caution when driving or operating machinery or when engaged in other activities that require balance and visual pakcage as this medication may cause dizziness, accommodation disorder, mydriasis, and blurred vision.
Major Since abarelix can cause QT prolongation, abarelix should be used cautiously, if at all, with other drugs that are associated with QT prolongation. Prescribers need to weigh the potential benefits and risks of abarelix use in patients with prolonged QT syndrome or in patients taking other drugs that may prolong the QT interval. Agents associated with a lower, but possible risk for QT prolongation and torsade de pointes TdP based on varying levels of documentation include packwge beta-agonists.
Moderate Use imsert a betaselective cardioselective beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patients lung and cardiovascular status closely.